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Abstract 1 
Introduction: The 2015 Global Meningococcal Initiative (GMI) meeting discussed the global 2 
importance of meningococcal disease (MD) and its continually changing epidemiology. 3 
Areas covered: Although recent vaccination programs have been successful in reducing 4 
incidence in many countries (e.g., Neisseria meningitidis serogroup [Men]C in Brazil, MenA 5 
in the African meningitis belt), new clones have emerged, causing outbreaks (e.g., MenW in 6 
South America, MenC in Nigeria and Niger). The importance of herd protection was 7 
highlighted, emphasizing the need for high vaccination uptake among those with the highest 8 
carriage rates, as was the need for boosters to maintain individual and herd protection 9 
following decline of immune response after primary immunization.  10 
Expert Commentary: The GMI Global Recommendations for Meningococcal Disease were 11 
updated to include: a recommendation to enable access to whole-genome sequencing as for 12 
surveillance, guidance on strain typing to guide use of subcapsular vaccines, and recognition 13 
of the importance of advocacy and awareness campaigns. 14 
 15 
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1. Introduction 1 
Meningococcal disease (MD) has a rapid onset with potentially life-changing consequences. 2 
MD is fatal in as many as 50–80% of untreated cases [1], and case fatality rates even in 3 
treated individuals are ~10–15% [2,3]. In addition, MD causes great morbidity, with 12–20% 4 
of survivors suffering significant clinical sequelae (e.g., paralysis, deafness, mental 5 
impairment, amputations, and seizures) [2,4–8]. According to the World Health Organization 6 
(WHO), there are no accurate estimates of the global burden of MD, a situation that is due to 7 
inadequate surveillance in many parts of the world. However, MD is often considered as 8 
endemic globally, although epidemics occur frequently in the meningitis belt in sub-Saharan 9 
Africa, as will be discussed further in this paper. Prevention strategies, in particular 10 
vaccination, have been shown to be extremely effective in controlling MD [9]. 11 
  12 
The most common presentations of invasive MD are meningitis and sepsis [10]. Localized 13 
and chronic infections resulting in pneumonia, endophthalmitis, arthritis, pericarditis, or 14 
myocarditis may also occur [3,10]. Although MD affects individuals of all ages, the highest 15 
rates of disease are found in infants <1 year old [1,11]. Peaks in incidence are also seen in 16 
adolescents as well as the elderly in some countries [12–16].  17 
 18 
The causative agent in MD is the bacterium Neisseria meningitidis. In a phenomenon known 19 
as carriage, N. meningitidis usually colonizes the mucosa of the human upper respiratory 20 
tract without resulting in MD. Carriage is frequent and involves ~10% of the general 21 
population [17], although rates are variable by age and setting, it is highest in adolescents 22 
and young adults (e.g., ≤27%), but far lower in older adults (e.g., ≤8%) and infants (<5%) 23 
[18,19]. Transmission of the bacterium from an infected individual to another person occurs 24 
via direct contact with droplet respiratory secretions [20]. 25 
 26 
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Genetic analysis of carriage strains has revealed a diverse range of organisms, with only a 1 
few of these found to be linked to MD [20,21]. Twelve serogroups of N. meningitidis have 2 
been identified, with six of these – N. meningitidis serogroups (Men) A, B, C, W, X, and Y – 3 
being responsible for virtually all invasive disease [1,11]. The epidemiology of MD is 4 
dynamic, with continuing changes in incidences of N. meningitidis serogroups and the 5 
emergence of new strain variants [1,22]. 6 
 7 
Although acquisition of meningococci usually results in asymptomatic carriage, local 8 
inflammation occurs in some cases along with invasion of mucosal surfaces, which provide 9 
access to the bloodstream [23] and can result in invasive MD (e.g., fulminant sepsis and/or 10 
meningeal inflammation) [23]. Additionally, a number of environmental factors such as 11 
exposure to cigarette smoke [24], that can cause inflammation of the nasopharyngeal 12 
mucosal surfaces, have also been associated with increased risk of invasive MD. 13 
 14 
Vaccination remains the key method for prevention of MD, and various vaccines and vaccine 15 
strategies have been developed. The key desired effects of vaccination are to protect those 16 
vaccinated from invasive MD when they are exposed, as well as to reduce acquisition and 17 
carriage, particularly of hyperinvasive isolates, and onward transmission. The coverage of 18 
the various types of anti-MD vaccines are summarized in Table 1. Polysaccharide vaccines 19 
(PSVs) have been available for >40 years and variously cover one or more of serogroups 20 
[1]. Protein-conjugate capsular vaccines are available [25], and when possible, these 21 
vaccines should be used in preference to the polysaccharide form, as they are more 22 
immunogenic, provide longer-lasting immunity and a stronger response to booster 23 
vaccination (i.e., more immune cell activity and antibody production) and do not induce 24 
hyporesponsiveness (i.e., show a poor or absent immune response) upon repeated use [11]. 25 
Combination conjugate vaccines are also available [26]. Vaccines using outer membrane 26 
vesicles (OMVs) have been used in outbreak control against specific strains since the 1980s 27 
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[27]. In addition, two vaccines designed to offer broad protection against MenB are available 1 
and were developed using subcapsular meningococcal antigens [28,29]. 2 
 3 
The Global Meningococcal Initiative (GMI) was established in 2009 to promote the 4 
prevention of MD worldwide through education, research, international cooperation, and 5 
vaccination [11]. The GMI is an international group of clinicians and scientists with expertise 6 
in MD immunology, microbiology, epidemiology, public health, and vaccination. Since its 7 
inception, several global and regional meetings have been held and these have resulted in 8 
the publication of recommendations, including the GMI Global Recommendations for 9 
Meningococcal Disease (Table 2), as well as regional situation reports [11,30–33]. 10 
 11 
In November 2015, the GMI convened an Expert Meeting in London, UK, titled ‘Prevention of 12 
Meningococcal Disease – Importance of Herd Protection’. The objectives of this meeting 13 
were to discuss the importance of herd protection and the potential impact this may have on 14 
MD; provide an update on surveillance, epidemiology, prevention, and control strategies 15 
from around the globe; highlight the lessons learned and experience gained from 16 
immunization strategies used in other countries; examine the health economics aspects of 17 
meningococcal vaccination strategies; and emphasize the critical need for disease 18 
awareness and advocacy with regard to MD prevention and control. 19 
 20 
2. Methods 21 
Participants included over 20 clinicians and scientists with expertise in various aspects of 22 
MD. The experts represented institutions in Africa, the Asia-Pacific region, Europe, Latin 23 
America, and North America. The meeting content comprised expert presentations, 24 
workshop sessions, and roundtable discussions.  25 
 26 
3. Results 27 
7 
 
3.1. Surveillance, epidemiology, and control: a global picture 1 
A series of presentations were given on MD surveillance, epidemiology, and control in 2 
different regions and countries from around the globe.  3 
 4 
3.1.1. Latin America 5 
Much of the data for Latin America are from the Sistema de Redes de Vigilancia de los 6 
Agentes Responsables de Neumonias y Meningitis Bacterianas (SIREVA II) network. This 7 
network includes regional reference laboratories employing deoxyribonucleic acid (DNA)-8 
based diagnostic technologies, such as PCR. Diagnostic methodologies for MD are 9 
described in detail elsewhere [34]. 10 
 11 
In Chile, N. meningitidis is subject to laboratory surveillance and requires immediate 12 
notification. Control measures implemented include vaccination (polyvalent conjugate 13 
vaccine used providing protection from MenA, C, W, and Y (note: other MD vaccines are 14 
licensed in Chile, but currently only the MenACWY conjugate is recommended and funded 15 
by the government), and the chemoprophylaxis of close contacts to prevent secondary 16 
cases. According to data from the Instituto de Salud Pública de Chile (ISPCH), since its first 17 
detection in 2010, the clone serogroup:serotype;subtype W:2a:P1.5,2:sequence type(ST)-11 18 
has undergone aggressive expansion, displacing serogroup B as the main cause of MD, with 19 
an incidence rate of >0.5/100,000 in 2014; in 2015, again according to ISPCH data, MenB 20 
also appeared to be increasing, with MenW possibly decreasing. A campaign using 21 
quadrivalent conjugate vaccine aimed at children aged between 9 months and 5 years was 22 
launched in late 2012; in 2014, an MD vaccination program using the MenACWY conjugate 23 
vaccine was included in the national immunization program (NIP) for all children aged ≥1 24 
year.  25 
 26 
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Since 2012, a National System of Health Surveillance has been in place in Argentina, where 1 
surveillance is both laboratory- and clinic-based, and a national reference laboratory 2 
receives an estimated 50% of isolates. Overall disease incidence is currently low 3 
(<0.7/100,000; data from the Ministerio de Salud de la Nación, Argentina); as in Chile, 4 
infants and young children are most affected. Epidemiology has been dynamic in the last 5 5 
years, with increased MenW circulation (W:2a:P1.5,2:ST-11 and W:2a:P1.2:ST-11 6 
accounted for 78% of all isolates). In Argentina, the MenW strains are distinct from the 7 
MenW strain that was first identified in Europe following the Hajj pilgrimage in 2000 (the so-8 
called ‘Hajj outbreak’ strain) [35], as is also the case with the strains in Chile. Argentina 9 
recently announced the plan to introduce the quadrivalent conjugate vaccine for infants at 3, 10 
5, and 15 months old, with an adolescent dose at 11 years. 11 
 12 
In Brazil, MenC remains the most common cause of disease; disease due to MenW has not 13 
increased as much as in Argentina or Chile, although the same MenW strain is involved [35]. 14 
Infant immunization with MenC conjugate vaccine follows schedule of immunization at 3 and 15 
5 months, with a booster dose at 12 months, and a single dose for toddlers ages 12 to 23 16 
months, but without a ‘catch-up’ campaign in older age groups [36]. The introduction of the 17 
MenC vaccine in Brazil in 2010 provided an immediate reduction in incidence rates of MD, 18 
especially in those children targeted for vaccination (Figure 1). Carriage rates in 19 
adolescents, in a study performed 2 years after the initiation of the infant immunization 20 
program, showed a prevalence of 10%, where serogroups were identified, serogroup C was 21 
the most common (1.32%), followed by serogroups B (0.99%), E (0.74%), Y (0.49%) and W 22 
(0.25%) [37]. Although plain PSVs offered protection against disease, they did not prevent 23 
acquisition of carriage of MenC in the 2010 outbreaks [38], which is why only conjugate 24 
vaccines are now used to control outbreaks.  25 
 26 
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In Mexico, MD is reportable through the Mexican National Epidemiologic Surveillance 1 
System; however, the true burden of MD is unknown. Not all isolates are submitted to the 2 
national reference laboratory, Instituto de Diagnóstico y Referencia Epidemiológicos. As a 3 
consequence, a limited number of isolates receive further characterization. In general, the 4 
number of reported MD cases has increased since 2002, although incidence rates are still 5 
extremely low, ranging from 0.01 to 0.04 per 100,000 in the 2010–2014 period (data from the 6 
Secretariat of Health, Mexico). Following the Metropolitan area outbreak in 2010, MenC has 7 
emerged as the prevalent strain, with some cases of MenY and MenB. Since 2010, a 8 
national response strategy has been developed that includes the availability of vaccines, but 9 
they are only used in case of outbreaks and, more recently, offered for travelers to high-risk 10 
countries. It is the opinion of the GMI, therefore, that N. meningitidis colonization in children 11 
and young adults might be a better indicator to detect at-risk target populations, in addition to 12 
demonstrating the presence and potential trigger of outbreaks. Such colonization data also 13 
suggest that inclusion of MD vaccination in national immunization programs could be a more 14 
effective protection strategy than reservation of vaccination for at-risk groups only.  15 
 16 
3.1.2. Asia-Pacific 17 
Approximately 4 billion people live in Asia [39], and there are two WHO regional offices 18 
covering Asia, namely the South-East Asia Region and the Western Pacific Region [40]. In 19 
South-East Asia, no country has been in either the WHO high (defined as >10 20 
cases/100,000 per year in this region [41]) or moderate (2–10 cases/100,000 per year in this 21 
region [41]) endemic rate categories for MD in the past 20 years. The true burden of MD is, 22 
however, unknown in the Asia-Pacific region for several reasons, including under-reporting, 23 
weak surveillance systems, lack of guidelines and standard case definitions, as well as lack 24 
of awareness. In some countries in the region (such as South Korea), MD has recently 25 
become a major public health issue due to more frequent outbreaks. In a move to rectify this 26 
10 
 
situation, a set of recommendations for surveillance, prevention, and control in the Asia-1 
Pacific region was developed at a regional meeting of the GMI in South Korea in 2014 [42]. 2 
 3 
Korea and Thailand are considered to have low endemic rates (defined for these countries 4 
as <2 cases/100,000 per year [41]). On the other hand, in the Western Pacific Region, New 5 
Zealand and Mongolia are considered high endemic areas, Australia is categorized as 6 
moderate, and the majority of countries have low endemic rates (again defined as <2 7 
cases/100,000 per year), including China, Japan, the Philippines, Singapore, and Taiwan 8 
[41]. Five of the major MD serogroups (A, B, C, Y, and W) are variedly present in Asia. 9 
MenA dominates in China, India, Bangladesh, Mongolia, and the Philippines during epidemic 10 
years, while MenB is seen in Australia and New Zealand. MenB, as a cause of sporadic 11 
cases, is seen in China, Indonesia, Japan, Malaysia, the Philippines, Singapore, Taiwan, 12 
and Thailand. MenC is likewise seen in China and Singapore; MenY has been documented 13 
in Japan and Taiwan and MenW in Singapore and Taiwan (2014 meeting of the GMI, 14 
manuscript submitted [41]).  15 
 16 
As with the quality of epidemiological data and vaccination programs are also variable within 17 
the region [43]. Only a few countries have meningococcal vaccination in their NIPs. China 18 
has routine mass countrywide immunization using PSV MenA in infants aged 6–18 months, 19 
given as two doses at 3-monthly intervals, and PSV MenA and C in young children, given as 20 
two doses at 3 and 6 years [44]. Comparatively, Australia uses a combined Haemophilus 21 
influenzae type b and MenC conjugate (Menitorix®, Table 1) in their NIP at 1 year [45]. 22 
Several meningococcal vaccines are available in the region, and the two predominating 23 
types are quadrivalent meningococcal (ACWY) conjugate vaccines (MCV4) and quadrivalent 24 
meningococcal PSVs (MPSV4), but the conjugate is preferred. Generally, across the region, 25 
its use is only for certain conditions (e.g., asplenia, and for other persons at risk), as well as 26 
for selected populations, such as those performing the Hajj pilgrimage and travelers to 27 
endemic countries [43]. 28 
11 
 
 1 
Meningococcal disease is not a reportable disease in Bangladesh; therefore, there are no 2 
national data on prevalence and incidence. However, cases are captured from the ongoing 3 
surveillance at a network of multiple hospitals in urban and rural Bangladesh (Saha SK, et al, 4 
unpublished data, cited with permission). Antibiotic use prior to specimen collection presents 5 
a barrier to obtaining viable meningococcal isolates, and most cases are now detected by 6 
PCR, with only a few isolates recovered from blood samples. MenA was predominant (90%; 7 
152/167) from 1994 to 2005. However, in subsequent years (2006–2015), MenB emerged 8 
gradually and established itself as the dominant serogroup (62%; 100/162) in Bangladesh. 9 
More than 50% of MD cases occur in the first year of life, and incidence in infants aged <1 10 
year ranges from 18 to 24/100,000 (Saha SK, et al, unpublished data). 11 
 12 
In Japan, cases are reported via the National Epidemiological Surveillance on Infectious 13 
Disease. The incidence of MD is low; 7–21 cases of meningococcal meningitis were 14 
reported annually between 1999 and 2012, but numbers have increased since 15 
meningococcemia was added as a notifiable disease condition in April 2013. Incidence was 16 
0.028/100,000 in 2014, and the predominant serogroup was MenY, followed by MenC and 17 
MenB. MenW is rarely reported. There have only been a few carriage studies to date; in 18 
these, an overall carriage rate of ~0.4–0.8% was observed [46,47].  19 
 20 
Quadrivalent meningococcal vaccines have been approved in Japan since 2014 and should 21 
be available on request to anyone who qualifies for the conditions shown on the package 22 
insert; however, who should be vaccinated remains a key question, and there is a need to 23 
define high-risk populations. Indeed, there are currently no recommendations for 24 
meningococcal vaccination in Japan, except for travelers to West Africa [48]. 25 
 26 
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3.1.3. Europe 1 
Incidence of MD is currently low in many parts of Europe, with differing distributions of 2 
serogroups and strains, and different vaccination policies in place. The official European 3 
case definition was last updated in 2012 [49], and there is continuing movement across 4 
Europe to adopt this common definition. The current clinical definition includes any person 5 
with at least one of the following: meningeal signs, hemorrhagic rash, septic shock, or septic 6 
arthritis. The laboratory criteria must include at least one of the following: isolation of N. 7 
meningitidis from a normally sterile site, including purpuric skin lesions; detection of N. 8 
meningitidis nucleic acid from a normally sterile site, including purpuric skin lesions; 9 
detection of N. meningitidis antigen in cerebrospinal fluid; and detection of Gram-negative 10 
stained diplococci in cerebrospinal fluid [49]. 11 
 12 
In the UK, the introduction of MenC conjugate vaccination in 1999 through routine 13 
immunization and a large catch-up campaign has resulted in significant and sustained 14 
disease reduction and the induction of herd protection [50]. Routine vaccination strategies 15 
have also been implemented in France, Germany, the Netherlands, and Spain, and these 16 
have dramatically reduced MenC MD incidence, particularly in the countries that have 17 
achieved high vaccine uptake rates among adolescents and young adults [49]. The key to 18 
maintaining this success will likely be to prevent acquisition of carriage by maintaining high 19 
antibody levels in adolescents. Hence, many countries, including the UK and Canada, have 20 
introduced booster vaccinations in this population.  21 
 22 
In Russia, reporting of MD is mandatory; however, there is a lack of typing facilities at the 23 
local level, although the availability of PCR-based methods is increasing. Therefore, the 24 
reported incidence is likely an underestimate, at 0.3–0.8/100,000 across the different 25 
regions, with most cases reported in young children [51]. The known serogroups are MenA, 26 
B, C, and W; MenW:clonal complex (cc)11 was first detected in Moscow in 2007, with the 27 
13 
 
number of cases increasing in 2014–2015 (Mironov K, unpublished data [52]). Although 1 
several vaccines are licensed, including multivalent conjugate types, the national vaccine 2 
strategy covers only at-risk groups, areas where the disease is endemic, and military 3 
recruits. Current barriers to vaccination are reported to include the underestimation of 4 
disease burden and limited pharmacoeconomic data. Improved surveillance systems, better 5 
physician and public awareness, and cost-effectiveness studies are also needed. 6 
 7 
3.1.4. Africa 8 
In South Africa, MD is endemic, with peaks in the winter and spring months. Any suspected 9 
MD is notifiable, and guidelines for treatment, prevention, and control are in place. National 10 
laboratory-based surveillance has been available since 1999, and enhanced surveillance 11 
has been in place at 25 hospital sites since 2003. Routine vaccinations are available for at-12 
risk groups. Incidence rates in South Africa vary by province, but are currently low overall 13 
(0.36/100,000 in 2014). The majority of disease is caused by MenW, followed by MenB; 67–14 
77% of disease is caused by MenA, C, W, or Y. The last peak in incidence, in 2006, was 15 
attributed to MenW [53], and MenW ST-11 (related to the so-called ‘Hajj strain’) remains the 16 
most prevalent, with infection rates highest in infants and young children [54]. Importantly, 17 
human immunodeficiency virus infection has been associated with an increased incidence of 18 
invasive MD, a higher risk of bacteremia, and a higher case fatality rate than in uninfected 19 
populations [55,56].  20 
 21 
Surveillance between 1998 and 2008 in Mozambique revealed 63 cases of MD, which were 22 
serogroup A, W, and Y. Of these, MenW was again the most prevalent (38/43; 88% cases), 23 
followed by MenA (3/43; 7.0% cases) [57]. As in South Africa, MenW ST-11 strains 24 
appeared to be the most prevalent (as of 2005) [57]. 25 
 26 
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In a number of countries worldwide, including several on the African continent, the Invasive 1 
Bacterial Vaccine-Preventable Diseases hospital sentinel surveillance program [58] is 2 
enabling PCR to be used for surveillance for a number of diseases, including MD.  3 
 4 
The sub-Saharan meningitis belt has a unique MD situation and special strategies in place, 5 
as discussed in Section 3.2.2.  6 
 7 
3.1.5. North America  8 
In North America (excluding Mexico), surveillance systems are in place and considered 9 
robust; active surveillance has been in place in the USA since 1995, and surveillance has 10 
been carried out in Canada since 1924 [59]. The incidence of invasive MD has remained low 11 
over the past several decades, and is continuing to decline [59]. This decline is thought to be 12 
multifactorial, including the introduction of mass vaccination campaigns and changes in 13 
behavioral risk factors [59]. MenB and MenC are the predominant serogroups reported in the 14 
region; however, localized outbreaks caused by various clones belonging to different 15 
serogroups are observed [59]. Outbreaks in recent years have led to the implementation of 16 
outbreak control and routine immunization vaccination programs in the USA and Canada. In 17 
the USA, routine anti-MenA,C,W,Y conjugate vaccination is recommended for otherwise 18 
healthy children at age 11 years, with a booster at age 16 (and catch-up program during 19 
adolescence) or from infancy onwards for those with certain high-risk conditions; MenB 20 
vaccination for those ages 16 through 23 is subject to individual clinical decisions [26]. 21 
Schedules vary across the regions and provinces of Canada, but in general anti-MenC 22 
vaccination is recommended during the first year and anti-MenA,C,W,Y conjugate 23 
vaccination during adolescence [60]. 24 
 25 
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3.2. Today’s remaining concerns, and key prevention and control strategies  1 
3.2.1. Prevention of carriage and the introduction of herd protection 2 
Conjugate vaccines are considered superior to plain PSVs in most aspects and also prevent 3 
acquisition of carriage and promote (indirect) herd protection (Figure 2) [61,62]. 4 
Consequently, their use is supported by the GMI [11]. In the UK, for example, adolescent 5 
boosters have been introduced to maintain herd protection that forms an integral part of the 6 
MenC control strategy [63]. Additionally, in Canada, an adolescent booster dose of MenC or 7 
MenACWY conjugate vaccine has been recommended in all provinces and territories [60]. 8 
 9 
In general, carriage is most frequent in young adults, with a prevalence of ~24% and 10 
approaching 100% in closed or semi-closed populations, such as military recruits and 11 
university students [18]. Since most transmission occurs in the carriage state, reducing 12 
carriage is pivotal to effective vaccination strategies. In such situations, conjugate vaccines 13 
provide herd protection by providing long-lasting protection and reducing nasopharyngeal 14 
carriage [61,64,65], for example, through the presence of high levels of mucosal antibodies, 15 
thus reducing total transmission in the population. 16 
 17 
Carriage studies can support and guide the introduction of meningococcal conjugate 18 
vaccines by showing which groups have the highest prevalence and are driving circulation of 19 
meningococci. They can also be used to determine the impact of the introduction of 20 
conjugate vaccines on carriage in vaccination programs. There are, however, few studies of 21 
meningococcal carriage in some ages/populations, but those that are available provide 22 
useful data. The lack of studies overall can be due to difficulties in sampling a representative 23 
population. Sample sizes of several thousand or more are necessary to evaluate changes 24 
when the prevalence of pathogens targeted by a vaccine is low; multicenter studies are 25 
preferable, because of the variability between sites. Sample collection and transport and 26 
analytical methods can all impact carriage data collection; it is also essential to have 27 
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rigorous quality control. Due to atypical strains, identification of N. meningitidis carriage 1 
remains problematic, and methods need to be standardized. In general, detection and 2 
characterization methods such as PCR [66], multi-locus sequence typing (MLST) [67], and 3 
whole-genome sequencing (WGS) [68] appear to be the most specific.  4 
 5 
3.2.2. MenA and the sub-Saharan meningitis belt 6 
The sub-Saharan meningitis belt comprises 26 countries across the sub-Saharan region and 7 
is characterized by very low rainfall and humidity in the dry season. Cases peak, and 8 
epidemics occur more frequently, in the dry season. During the 1996–1997 MD epidemic, 9 
there were >250,000 cases of MenA, prompting African governments and the WHO to 10 
demand a new conjugate vaccine for Africa [69]. MenW, MenX, and MenC have also caused 11 
epidemics in the sub-Saharan meningitis belt. Between 2004 and 2010, 19 sequence types 12 
belonging to six clonal complexes were identified, with MenA of the ST-5 cc identified as the 13 
predominant disease-causing strain, responsible for ~80% of epidemics [67,70]. The most 14 
recent large-scale MenA epidemic was in 2009 [71]: during this year alone, nearly 90,000 15 
cases of meningitis were reported – 50,000 of which were in Nigeria [71]. 16 
 17 
In response to the threat of MenA epidemics, MenAfriVac® (Table 1) was developed and 18 
licensed in India and awarded pre-qualification by the WHO in 2010 [69]. The introduction 19 
strategy for MenAfriVac® was to induce rapid direct and indirect (i.e., herd) protection by 20 
vaccinating individuals aged 1–29 years in mass campaigns [72] spanning over 1–4 years, 21 
and to protect new birth cohorts through a routine expanded program of immunization (EPI) 22 
or follow-up campaigns. This staggered approach to vaccination was, in part, due to large 23 
populations being spread over a wide area. Risk assessments were put in place [73] to 24 
define priority areas and to estimate target populations before vaccine introduction, and by 25 
November 2015, 237 million people had been vaccinated [74]. Enhanced surveillance and 26 
outbreak response capacity are an essential part of epidemic preparedness and response, 27 
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enabling a quick response to new outbreaks and provision of adequate treatment and 1 
containment. Case-based surveillance is being undertaken in some countries, such as 2 
Burkina Faso and Niger, and uses epidemiological and laboratory data. Countries are 3 
supported by the WHO and international collaborating laboratories. The incidence of MenA 4 
has now dramatically decreased [65,69], and the vaccine has also had a dramatic impact in 5 
reducing carriage [65]. Between 1 January and 12 May 2013, there were 9249 suspected 6 
meningitis cases with a case fatality ratio of 9.3% (857 deaths) across 18 countries – the 7 
lowest number of cases recorded during the epidemic season in the last 10 years [115], with 8 
the majority of cases occurring during 2009 (Figure 3) [75]. Under enhanced surveillance in 9 
2014, 7585 meningitis cases and 610 deaths were reported across the African meningitis 10 
belt, with the WHO region-specific epidemic threshold of >100 cases/100,000 [41] crossed in 11 
districts of Burkina Faso, Cameroon, the Central African Republic, Chad, Ethiopia, Gambia, 12 
Ghana, Guinea, Mali, Niger, Nigeria, Senegal, South Sudan, and Sudan [76]. The WHO 13 
recommendations for EPI and ‘catch-up’ schedules and dosages are being rolled out across 14 
the sub-Saharan meningitis belt [72,77]. Following the introduction of MenAfriVac®, the WHO 15 
now recommends that the vaccine is incorporated into the routine EPI schedule within 5 16 
years. Modeling suggests that, if routine EPI is not followed with subsequent immunization, 17 
epidemics could occur within 15 years following mass campaigns [59,72]. 18 
 19 
Subsequent to MenAfriVac® introduction, MenW became the predominant strain across the 20 
sub-Saharan meningitis belt. However, MenC appears to have re-emerged recently, having 21 
not been responsible for outbreaks in the sub-Saharan meningitis belt since 1979 [78]; in 22 
Nigeria, it increased from 452 suspected cases in 2013 to 796 suspected cases in 2014. 23 
Then in 2015, the outbreak expanded rapidly, with 2845 suspected cases in Nigeria, and 24 
8502 cases in the bordering country of Niger (totaling 11,347 suspected cases) [79]. This is 25 
a new MenC strain (ST-10217) [79] that seems to have spread from a single source in 26 
Nigeria; it is genetically unrelated to the epidemic clones found in Africa in previous decades 27 
or to the rare serogroup C isolates that have circulated elsewhere in the world since the 28 
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1980s [80]. It probably originated from a carrier isolate that has acquired serogroup C 1 
capsule and other virulence genes by recombination (Caugant DA, unpublished data, cited 2 
with permission). The clone is still evolving and has now spread to neighboring countries. 3 
Affected populations are unlikely to have immunity against MenC, and the prospect of a 4 
major epidemic is of great concern. 5 
 6 
3.3. The rising concern of MenW: epidemiology and control  7 
3.3.1. MenW epidemiology 8 
Serogroup W was discovered in 1968 and, until 2000, was responsible for a relatively small 9 
number of cases worldwide. A pivotal recent event was the emergence and epidemic 10 
situation of MenW in Hajj pilgrims in Saudi Arabia, the UK, and France in 2000, 11 
subsequently in sub-Saharan Africa, and elsewhere globally [81,82]. The Hajj cluster of N. 12 
meningitidis represents an expansion of one MenW clone within the ST-11/ET-37 complex 13 
[35,83]. However, some other recent MenW outbreaks (such as seen in Brazil, Portugal 14 
[84,85], Sweden [86], and Taiwan [2014 meeting of the GMI, manuscript submitted] [41]) 15 
have been due to other ST-11 variants. Although the hypervirulent clone W:2a:P1.5,2:ST-11 16 
emerged 10 years ago in Brazil [87], incidence rates have become far higher in Argentina 17 
and Chile. In Chile, for example, the MenW incidence rate had risen to >0.5/100,000 by 18 
2014, compared with <0.1/100,000 in 2010 (data from the ISPCH, Laboratorio de Agentes 19 
de Meningitis Bacteriana, Santiago, Chile); by 2012, 58% of MD was MenW [88]. The MenW 20 
ST-11/ET37 cc now appears to be endemic in the Southern Cone region [89]. In the UK, 21 
MenW has also been increasing; the new isolates belong to the ST-11/ET-37 complex but, 22 
again, appear to be different from the Hajj strain, although close to the South American 23 
isolates [35]. 24 
 25 
Thus, there appears to be an ongoing multifocal emergence of new MenW isolates by 26 
means of an old event of capsule switching, and MenW/cc11 isolates – other than those 27 
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from the Hajj outbreak – have contributed to a significant proportion of MenW/cc11 cases 1 
globally. Surveillance therefore needs to combine exhaustive reporting and typing and, if real 2 
insight is to be gained from what is taking place with MenW, WGS typing is required. To 3 
date, isolates from waves of MenW/cc11 infection have been found to have differences in 4 
the genes encoding factor H-binding protein (fHbp), fetA, nitric oxide reductase, and nitrite 5 
reductase [35,90]. 6 
 7 
3.3.2. MenW control 8 
Vaccination strategies for controlling MenW and other N. meningitidis strains using 9 
multivalent conjugate vaccines being rolled out in a number of countries. An immunization 10 
campaign began in 2012 in Chile with the quadrivalent conjugate vaccine (MenACWY; 11 
Menveo®; Table1), initially targeting children aged from 9 months to <5 years. The incidence 12 
of MD in this age group before and after introduction of quadrivalent N. meningitidis 13 
(MenACWY) vaccination is shown in Figure 4. Since 2012, approximately 1 million children 14 
have been vaccinated, and vaccine uptake of 95% has been attained in these age groups 15 
(data from ISPCH Laboratorio de Agentes de Meningitis Bacteriana). In addition, since 2012, 16 
a temporary vaccination strategy was established in which children aged from 9 months to 5 17 
years were vaccinated, and infants from 9 months old were given a second dose to increase 18 
protection. The vaccines Menactra® (Table 1) and Menveo® have been used as part of this 19 
temporary vaccination strategy. On 1 January 2014, vaccination became part of the national 20 
immunization schedule and was mandatory for all children aged ≥1 year, with a one-dose 21 
schedule of Nimenrix® (Table 1) implemented. Overall, however, the number of cases of 22 
MenW is still increasing in Chile in children between 9 months and 5 years of age (data from 23 
ISPCH Laboratorio de Agentes de Meningitis Bacteriana) (Figure 4). In Argentina, between 24 
2012 and 2014, there were 848 cases of MD, with an incidence rate of 0.7/100,000 25 
population; 43% of these were in infants aged <2 years [91]. Around 50% of cases were 26 
MenW, and 41% were MenB [91]. Argentina recently announced the decision to implement 27 
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quadrivalent conjugate vaccination in infants (at 3, 5, and 15 months old). Adolescents aged 1 
≥11 years are to receive one dose [91]. In the UK, MenW has increased rapidly since 2 
2011/2012 [92]. A vaccination program was introduced in August 2015, for teenagers and 3 
university freshers, using MenA,C,W,Y conjugate vaccines, with the intention of inducing 4 
direct and herd protection [63]. Although it is anticipated that conjugate vaccines will have a 5 
similar effect on the carriage of W as they have had on serogroups A, C, and Y, this has yet 6 
to be demonstrated. 7 
 8 
3.4. Decreasing the threat of MenB: implementation of MenB vaccines 9 
Capsular vaccines cannot be used for MenB due to similarities of the polysaccharide with 10 
human polysialic acid on neural cell adhesion molecules; therefore, vaccines targeting MenB 11 
have been developed using subcapsular proteins. Earlier vaccines based solely on OMVs 12 
could only offer protection against homologous strains and needed multiple doses to induce 13 
broader protection [27]. Bexsero®, a multicomponent vaccine, was developed by reverse 14 
vaccinology and comprises an OMV used in a New Zealand outbreak and three recombinant 15 
proteins – the neisserial heparin-binding antigen (NHBA), the Neisseria adhesin A (NadA), 16 
and the fHbp [29]. Clinical studies were conducted in infants, toddlers, and adolescents [93]; 17 
>5000 infants/toddlers and 19,000 adolescents/adults have now been vaccinated. Bexsero® 18 
was approved by the European Medicines Agency in 2013 for individuals ≥2 months of age, 19 
and by the US Food and Drug Administration (FDA) in 2015 for ages 10 to 25 years [94,95]. 20 
The vaccine is reactogenic, with transient fever seen in infants peaking ~6 h after 21 
vaccination and resolving within 2–3 days, particularly after the primary dose; the reaction 22 
can be increased by concomitant administration with other routine infant vaccinations, but is 23 
manageable with paracetamol, with only 2–3% of patients requiring additional medical 24 
attention [93]. A second subcapsular vaccine, Trumenba®, contains two fHbp variants 25 
[29,96], and was approved by the FDA in 2014 for use in adolescents and young adults 26 
aged 10–25 years [97].  27 
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 1 
Measurement of strain coverage with subcapsular vaccines can be complex, as they 2 
comprise multiple antigens that vary between strains and may be expressed at variable 3 
levels. The Meningococcal Antigen Typing System (MATS), which is based on an enzyme-4 
linked immunosorbent assay, and either phenotypic or genotypic PorA typing, [98] has been 5 
used for strain characterization to evaluate potential strain coverage with Bexsero®. Using 6 
this method, worldwide strain coverage has been estimated at ~66–91% [92]. Some 7 
coverage of non-MenB strains by the vaccine has also been reported, with 70% coverage of 8 
MenW and MenY strains, but only ~20% for MenC. Coverage of African epidemic MenX 9 
isolates has also been suggested [99]. 10 
 11 
In 2013, MenB outbreaks occurred at two universities in the USA (Princeton, NJ and the 12 
University of California, Santa Barbara); Bexsero® vaccination was conducted under the 13 
FDA’s expanded access investigational new-drug protocol, and approximately 5500 and 14 
17,000 individuals were vaccinated at these universities, respectively  . For the Princeton 15 
outbreak, MATS analysis showed that the strains were sufficiently reactive with the Bexsero® 16 
fHbp and NHBA to invoke an effective immune response, but were mismatched for the NadA 17 
and PorA antigens [102]. Vaccination uptake rates of 97% (first dose) and 92% (second 18 
dose) were achieved. Carriage was not formally assessed, but the occurrence of a ninth 19 
case in an unvaccinated Princeton student who had close contact with vaccinated 20 
undergraduates implies that the strain continued to circulate after vaccination [100,101]. 21 
Since September 2015, Bexsero has been introduced into the UK’s routine infant 22 
immunization strategy [63], and enhanced surveillance – that includes genotyping and MATS 23 
– is ongoing as part of this program [103]. 24 
 25 
Vaccination programs (e.g., for MenC [consisting of one to three doses of MenC conjugate 26 
vaccine in infancy, with a booster dose of MenC conjugate or MenACWY conjugate vaccine 27 
at 12–15 years old]) have been in place for a number of years in Canada; MenB, however, 28 
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has recently become the most prevalent serogroup in Quebec and Ontario (data from Public 1 
Health Agency of Canada, 2014 shown in Figure 5) [104,105], although the reasons for 2 
differences in prevalence from other provinces are unclear. Most of the isolates recently 3 
characterized in Quebec have been ST-269 clones that express two variants of the antigens 4 
fHbp and NHBA potentially covered by Bexsero® [106]. Bexsero® was licensed in 2013 in 5 
Canada and vaccination is proposed for high-risk groups [104,107,108], with current 6 
recommendations based on various criteria, including low disease burden, program cost, 7 
lack of effectiveness and reactogenicity data [107,108]. In one area in Quebec, MenB MD 8 
incidence reached >3.5/100,000 in the period 2006–2012, and a decision was taken to use 9 
Bexsero® based on several strands of evidence, including phenotyping and genotyping of 10 
strains. More than 50,000 people between the ages of 2 months and 20 years were 11 
vaccinated on a two-dose schedule [100]. The vaccine uptake rate for one dose was 82%, 12 
but this went down to 70% for at least two doses, mainly due to low uptake in older 13 
adolescents and young adults [100]. Based on a modeling analysis, it was estimated that the 14 
vaccination campaign reduced disease incidence by 77% [109]. In May 2014, more than a 15 
year after the start of the immunization campaign, no new MenB cases had been observed 16 
among vaccinees, with two cases observed among non-vaccinated adults [109]. The strain 17 
therefore continues to circulate and, as in the US university outbreaks, there is no evidence 18 
of indirect protection. Despite the lack of data supporting herd protection with these MenB 19 
vaccines, there are data suggesting that OMV vaccines can reduce carriage [110]. 20 
 21 
3.5. Advocacy and awareness in MD 22 
Around the world and in many different countries, many organizations play important roles in 23 
raising awareness of MD and advocating for clinicians, as well as for patients and their 24 
families. The Meningitis Research Foundation (MRF), for example, is a UK-based charity 25 
that funds research, promotes education and awareness of MD, and provides support for 26 
those affected by meningitis. For example, in the case of Bexsero® in the UK, following the 27 
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interim statement from the UK Joint Committee on Vaccination and Immunisation that 1 
vaccination was unlikely to be cost-effective at any vaccine price, the MRF highlighted the 2 
consequences and costs of survival with life-limiting sequelae. In addition, the MRF 3 
conducted campaigns to engage with clinicians and experts in the field, as well as public 4 
campaigns based on real-life personal stories in a range of settings. This coordinated 5 
collective effort by parent and patient advocacy, health experts, and key opinion leaders 6 
contributed to the decision to approve Bexsero® for use in the UK’s vaccination program 7 
[111]. 8 
 9 
On a global scale, another such organization, the Confederation of Meningitis Organisations 10 
(CoMO) represents 45 organizations from 28 countries [112]. CoMO has a scientific advisory 11 
panel comprising experts from around the globe, and uses non-government organizations 12 
and ‘people advocate’ conferences, as well as meetings with politicians in Europe and 13 
campaigning on social media. It provides a global platform for its member organizations to 14 
campaign on meningitis awareness and vaccination, and organizes World Meningitis Day 15 
annually in April [113]. CoMO has commissioned research into the long-term cost of    16 
meningitis [114], and is currently advocating for a ‘life-course’ immunization initiative (for 17 
infants, adolescents, and the elderly) [115]. 18 
 19 
3.6. The role of modeling in MD control and prevention  20 
To improve understanding of the epidemiology of an infection, make predictions about future 21 
incidence under particular conditions or interventions, and identify data gaps, transmission 22 
dynamic mathematical models can be developed and applied. Modeling studies of 23 
meningococcal infection reinforce the importance of herd protection following mass ‘catch-24 
up’ campaigns and illustrate that conjugate vaccines’ effect on carriage was crucial to the 25 
success of the MenC and MenAfriVac® vaccine programs [18,72,116]. Such models are 26 
used to best effect in combination with data from surveillance, clinical trials, and carriage 27 
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studies [61,64,65]. The clinical evidence for the impact of subcapsular vaccines (such as 1 
Bexsero®) on MenB carriage is currently unclear as few data have been published [117]; 2 
however, models can help us to identify knowledge gaps and enable testing of how 3 
hypothetical effects on carriage might impact different potential vaccination strategies. 4 
 5 
A workshop on modeling vaccination strategies held during the meeting explored how 6 
modeling can be used in combination with surveillance and vaccine information to guide 7 
decision making. Transmission models should be used for MD, as the occurrence of 8 
infection depends on carriage in other members of the population; risks of infection are 9 
dynamic and non-linear [72,116,118]. In the UK, models have been used to synthesize 10 
different types of evidence (e.g., in disease burden, natural history, and vaccine effects); to 11 
make predictions about vaccine impact and also to aid optimum implementation of 4CMenB 12 
vaccination; modeling has been used to evaluate factors including herd protection; to 13 
compare schedules, strategies, and policy options; and to estimate the cost-effectiveness of 14 
vaccination [106,116,118,119]. It was agreed by the GMI that, to predict future incidence and 15 
develop a vaccination strategy during an outbreak, incidence and carriage data, and the 16 
response threshold selected, are the most important factors. It was also agreed that, when 17 
deciding whom to vaccinate and which vaccine to use, the availability of sufficient vaccine 18 
and the vaccine’s ability to interrupt carriage were the most important factors. Regarding 19 
health economic analyses, it was noted that these are only reliable when working from 20 
robust data. The GMI agreed that economic modeling could be conducted, but it requires 21 
reliable data on the burden of the disease and should not be the sole driver of decision 22 
making. 23 
 24 
4. Discussion  25 
The presentations on surveillance, epidemiology, and control from around the globe given at 26 
this GMI meeting highlight disparities in the quality and availability of surveillance networks 27 
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and technologies, such as PCR and WGS. The current GMI Global Recommendations for 1 
Meningococcal Disease [11] underline the need to increase the availability and quality of 2 
laboratory surveillance in order to understand the true burden of MD (Table 2). The role of 3 
enhanced surveillance in demonstrating the success of the MenAfriVac® campaigns [71] and 4 
in detecting emerging MenW outbreaks in Latin America and the UK [120] illustrates the 5 
importance of high-quality data that should include typing by WGS [120]. There is a need for 6 
continued vigilance in the face of the emergence of new clones requiring maintenance of 7 
high-level surveillance where it is already attained and improvement in countries where 8 
systems are weak. Also, although vaccination programs are effective in combating MD, 9 
meningococcal vaccines are still not available as part of routine childhood vaccination 10 
programs in many countries.  11 
 12 
As the GMI, we have developed a number of recommendations. First, conjugate vaccines 13 
are recommended by the GMI, as in most aspects they are superior to plain PSVs (Table 2). 14 
In addition, the GMI recognizes herd protection as being a significant component of control 15 
in MD, with evidence presented from several studies and countries showing that adolescent 16 
doses provide individual and herd protection. It is important to note, however, that a number 17 
of factors, including disease prevalence, carriage rates, and vaccine type, may influence the 18 
level of vaccination coverage required to attain herd immunity [121] (for example, in the 19 
African meningitis belt, a vaccination rate of 70% was considered to have afforded herd 20 
immunity [72]). 21 
 22 
The success of MenAfriVac® in Africa and MenC vaccination in several European countries, 23 
Australia, and Canada demonstrates the importance of building herd protection through 24 
adolescent and ‘catch-up’ campaigns. It was noted that, in different countries, adolescent 25 
vaccinations were undertaken at different ages (e.g., at 11 years in Argentina, but in older 26 
teenagers in the UK). A number of factors seem to govern such decisions, including the 27 
practicalities of timing to attain maximum vaccine uptake rates. We suggest that, as 28 
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socioeconomic factors – such as age, differences in levels of close physical contact, starting 1 
smoking, and so on – may differ between and even within countries, local differences need 2 
to be taken into account when devising vaccination strategies to ensure that herd protection 3 
is optimized. Although carriage studies are complex to undertake, evaluation of the age 4 
distribution of carriage, estimation of the case–carriage ratios, and identification of the clones 5 
being carried are essential to fully understand the relationships between carriage and 6 
outbreak strains. We also believe that MLST [67] and WGS [120] may be the most effective 7 
DNA analysis methods for carriage studies. 8 
 9 
The extensive data presented on MenW from around the globe again highlight the 10 
importance of routine and ‘catch-up’ vaccination programs for both direct and indirect 11 
protection. The data show that the recent expansion of MenW has been through the 12 
emergence of sub-clones that are spreading globally [120]. Again, such observations 13 
highlight the need for active surveillance systems that can provide accurate data through 14 
WGS, for example. Intriguingly, one strain can appear to behave differently in different 15 
countries; for example, the hypervirulent MenW strain that emerged in Brazil has become far 16 
more prevalent in recent years in Argentina, Chile, and the UK. Yet again, such observations 17 
underline the need for strong local surveillance networks and locally tailored control 18 
measures. In addition, combination of WGS and new molecular techniques such as 19 
proteomic gene expression analysis may provide additional detail on the biological 20 
characteristics of individual strains and thus further aid our understanding of emergence 21 
events [122]. 22 
 23 
The report presented on the outbreak of MenW at the 2015 World Scout Jamboree in Japan 24 
[86] illustrates the ever-present risk and need for preventive measures such as vaccination 25 
for participants in events where large numbers young people are gathered. It also underlines 26 
the importance of maintaining immunity in adolescents and young adults. 27 
 28 
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Subcapsular MenB vaccines are now available and have been used effectively in outbreak 1 
control [100,102,109], and are also now included in routine infant vaccination 2 
recommendations in the UK. To evaluate the level of coverage provided by these vaccines, 3 
such as in an outbreak situation, accurate data on presence and expression of the various 4 
vaccine-related antigens in the active strain are required. For this, again, good-quality 5 
surveillance with access to MATS and DNA analysis technologies, especially WGS, are 6 
required. There is still uncertainty about the ability of these vaccines to eliminate MenB 7 
acquisition/carriage, and further data are needed in this area. 8 
 9 
The importance of raising awareness and of advocacy in promoting the prevention and 10 
control of MD was highlighted by the work of the MRF and the CoMO. Indeed, these 11 
organizations continue to play an important role in activities to support the introduction and 12 
expansion of vaccination and surveillance programs. 13 
 14 
As noted above, modeling can be used to help us understand the impact of 15 
carriage/acquisition reduction on indirect protection and to enable longer-term predictions. 16 
The GMI agreed that models are used to best effect in combination with data from various 17 
sources, including disease surveillance, clinical trials, and carriage studies. 18 
 19 
5. Summary 20 
During the 2015 GMI meeting, presentations showed how vaccination programs have been 21 
successful in reducing MD incidence in many countries; however, it was also described how 22 
new MenW clones present a threat, as does the emergence of a new MenC strain in the 23 
African meningitis belt. As a result of the findings presented, the GMI recognized the 24 
importance of ongoing vigilance and called for continued support and expansion of 25 
vaccination and surveillance programs. The importance of building herd protection and 26 
stopping acquisition for the prevention of transmission of MD was also discussed. The GMI 27 
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agreed that vaccination of those age groups with the highest carriage rates (particularly 1 
adolescents) is important for this. With this in mind, the GMI also called for vaccination 2 
programs for protection during large gatherings of young people in close contact. 3 
Presentations from the MRF and the CoMO showed how such organizations are key to 4 
ensuring continuation and growth in all of these areas. 5 
 6 
Updates to the GMI Global Recommendations for Meningococcal Disease were determined 7 
during the meeting based on the findings presented (Table 3). The GMI agreed that there is 8 
a need for a recommendation to enable access to WGS as part of surveillance programs 9 
and also for DNA sequence data to be publicly available. It was also agreed that guidance 10 
on the antigen expression criteria that indicate use of subcapsular vaccines should be 11 
included in the recommendations. Finally, the GMI agreed that support for MD advocacy and 12 
awareness campaigns should be included in the GMI Global Recommendations for 13 
Meningococcal Disease. 14 
 15 
6. Expert commentary 16 
MD remains an important health concern in many regions across the globe, particularly 17 
Africa, where morbidity and mortality rates are still high, as well as in Asia, where the true 18 
burden of MD is uncertain. However, health policy leaders, scientists, and clinicians in these 19 
regions (and individual countries) can learn from the experiences, insights, and strategies of 20 
others from across the globe where MD has been prevented and controlled with great 21 
success. Indeed, much can be learnt from the Latin American experience and control of 22 
MenW, as well as from the control of MenA in the African meningitis belt, of MenC in 23 
Australia, Brazil, Canada, and Europe, and of MenB in the UK and Canada. 24 
 25 
Since the introduction of meningococcal vaccines, the world has seen a substantial 26 
reduction in the burden of MD. Outbreaks continue to occur in many areas of the world. The 27 
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reasons for this are multifactorial and include: relatively low vaccination uptake rates; poor 1 
surveillance and control systems; lack of standardized case definitions and diagnostic 2 
assessments; lack of herd protection; failure to vaccinate those currently at risk; strain 3 
changes; rise of serogroup(s) not covered by currently used vaccines; and the general 4 
unpredictability of MD epidemiology. 5 
 6 
Moving forward, a key strategy to further reduce/interrupt MD transmission, beyond the 7 
levels noted today, would be to induce herd protection in populations where it is currently 8 
lacking. Data suggest that herd protection can be achieved with conjugate vaccines by 9 
immunizing those who are most likely to be carriers and thus targeting the driving force of 10 
transmission (i.e., adolescents and young adults), as opposed to immunizing those in whom 11 
only direct protection is gained (i.e., infants and young children). Some countries are 12 
currently implementing (or at least recommending) such strategies (e.g., the USA and UK). 13 
Of course, achieving and sustaining herd protection will be a challenge in itself and is likely 14 
to require high vaccination uptake rates in populations where vaccine uptake is currently low. 15 
While the experience in many countries, both developed and developing, proves that 16 
decreasing the overall incidence of MD and control of outbreaks is possible, coordinated, 17 
sustained, and long-term strategies will be required in each country in order to reach the 18 
goals of lowering mortality and morbidity due to MD. 19 
 20 
7. Five-year view 21 
In the next 5 years, the epidemiology of MD will most likely continue to be dynamic and 22 
change across the globe, as enhanced surveillance systems and prevention and control 23 
strategies are being implemented. Furthermore, it is likely that localized outbreaks that are 24 
potentially controllable through vaccination programs will continue to occur in places where 25 
systems are weak or lacking. In addition, the emergence of new strains is likely to be an 26 
issue, such as the ST-10217 in Nigeria and Niger and the variants of ST-11/ET-37 cc MenW, 27 
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and the spread of other hypervirulent strains. Constant vigilance and high-quality MD 1 
surveillance will be needed. 2 
 3 
New multi-omic technologies and bioinformatics tools continue to develop, with genetic 4 
techniques such as real-time PCR and WGS, as well as gene expression methods such as 5 
transcriptomic and proteomic analyses, which enable even more in-depth strain 6 
characterization, becoming more widely available. Such techniques could become more 7 
accessible to surveillance laboratories at least on a regional level, if not nationally, within the 8 
next 5 years, and should improve not only surveillance but also understanding of emergence 9 
of particular strains. It would be hoped that availability of higher-quality epidemiological data 10 
from such sources could be used as a driver for implementation of effective routine and 11 
emergency vaccination programs. In parallel, the increasing availability of carriage data, 12 
together with the availability of new DNA technologies and modeling data, should enable 13 
effective targeting of age groups and populations in whom carriage is greatest, and where 14 
immunization would be best employed to develop effective herd protection. The GMI agrees 15 
that vaccination of the age groups with the highest carriage rates (particularly adolescents) is 16 
important for this, and should be implemented, or at least recommended, in more countries 17 
in the next 5 years. 18 
 19 
The GMI recognizes the importance of ongoing vigilance and has called for continued 20 
support and expansion of vaccination and surveillance programs. Organizations such as the 21 
MRF and the CoMO will be key to ensuring the continuation and growth of surveillance and 22 
vaccination programs during the coming years. 23 
 24 
When employed in organized vaccination programs, new vaccines, such as the quadrivalent 25 
MenACWY conjugate vaccines and the MenA conjugate MenAfriVac®, have already made 26 
dramatic contributions to the control of MD through providing direct protection and, 27 
potentially, herd protection. It is anticipated that, if such programs are continued and 28 
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expanded, impact on MD will also continue. The new MenB vaccine Bexsero® has also now 1 
shown effectiveness in real-world outbreak situations and, within the next 5 years, its effects 2 
within a national infant immunization program and on carriage should be better understood. 3 
 4 
Finally, availability of high-quality surveillance data in the future is also necessary so that a 5 
state of preparedness is maintained and suitable vaccines are available, or can be rapidly 6 
made available should newly emergent strains become a threat (e.g., MenC in the sub-7 
Saharan meningitis belt). 8 
 9 
All of these points are covered by the GMI Global Recommendations for Meningococcal 10 
Disease. If they are implemented, through a combination of improved disease surveillance, 11 
the availability of conjugate vaccines, and advocacy to build disease awareness, it might be 12 
possible to have a substantial impact on the incidence of MD globally within the next 5 years. 13 
8. Key issues 14 
• The GMI is an international group of clinicians and scientists with expertise in MD 15 
immunology, microbiology, epidemiology, public health, and vaccination; it was 16 
established to promote the prevention of MD worldwide through education, research, 17 
international cooperation, and vaccination. 18 
• The GMI has previously produced a set of Global Recommendations for Meningococcal 19 
Disease (Table 2). 20 
• More than 20 clinicians, scientists, and public health experts representing institutions in 21 
Africa, the Asia-Pacific region, Europe, and Latin America convened in November 2015 22 
to discuss topics including herd protection, surveillance, epidemiology, prevention, and 23 
control strategies. 24 
• Although vaccination programs have been successful in reducing MD incidence in many 25 
countries, it was agreed that new MenW sub-clones present a threat, as does the 26 
emergence of a new MenC strain in the sub-Saharan meningitis belt. 27 
32 
 
• The GMI recognizes the importance of ongoing vigilance in the face of this dynamic 1 
disease and called for continued support and expansion of vaccination and surveillance 2 
programs. 3 
• Building herd protection and stopping carriage are important, as they prevent 4 
transmission of MD; therefore, vaccination of those age groups with the highest carriage 5 
rates (particularly adolescents) is necessary, as are vaccination programs for protection 6 
during large gatherings of young people in close contact. 7 
• A number of additions to the GMI Global Recommendations for Meningococcal Disease 8 
were agreed: 9 
o There is a need for a recommendation to enable access to WGS as part of 10 
surveillance programs, and also for DNA sequence data to be publicly available.  11 
o Guidance on the antigen expression criteria that indicate use of subcapsular vaccines 12 
should be included in the recommendations. 13 
o The GMI recognizes the importance of MD advocacy and awareness campaigns and 14 
agrees that support for such activities should be included in the GMI Global 15 
Recommendations for Meningococcal Disease. 16 
 17 
Acknowledgments 18 
We confirm that all authors contributed in the development of this manuscript and that they 19 
all approved the final article. 20 
Medical writing support was provided by Shelley Lindley, PhD, of PAREXEL, which was 21 
funded by Sanofi Pasteur. 22 
 23 
Financial and competing interests disclosure 24 
R.B. and J.F. perform contract research on behalf of Public Health England for Baxter 25 
Biosciences, GlaxoSmithKline, Novartis, Pfizer, Sanofi Pasteur, and Sanofi Pasteur MSD. 26 
P.A., J.C., R.D., G.E.A., C.H., D.H., H.K., S.K.S. have no conflicts of interest to declare. 27 
33 
 
D.A.C. has performed in the past contract research on behalf of the Norwegian Institute of 1 
Public Health for Novartis, Pfizer, and Sanofi Pasteur. H.C. has received an honorarium from 2 
Sanofi Pasteur for running a GMI modeling workshop paid to her employer. Furthermore, 3 
H.C. is supported by the National Institute for Health Research [PDF-2012-05-245] and is a 4 
member of the National Institute for Health Research Health Protection Research Unit (NIHR 5 
HPRU) in Evaluation of Interventions at the University of Bristol, UK. S.S. has received 6 
grants from Pfizer, outside the submitted work. P.D.W. has received research grants and 7 
reimbursements of travel expenses from vaccine manufacturers including GlaxoSmithKline, 8 
Novartis, Sanofi Pasteur, and Pfizer, as well as from governmental agencies including the 9 
Quebec Ministry of Health and Social Services, Health Canada, and the Public Health 10 
Agency of Canada. J.C. has received research grant support from GlaxoSmithKline, 11 
Novartis, and Sanofi Pasteur; however, no conflict of interest relevant to this manuscript is 12 
reported. M.-K.T. performs contract research on behalf of Institut Pasteur for 13 
GlaxoSmithKline, Novartis, Pfizer, and Sanofi Pasteur. C.T. received a consulting payment 14 
from GlaxoSmithKline in 2013 for critical review of a health economic model of 15 
meningococcal vaccines and an honorarium from Sanofi Pasteur in 2015 for running a GMI 16 
modeling workshop. J.A.V. performed contract research on behalf of Institute of Health 17 
Carlos III for Baxter Biosciences, GlaxoSmithKline, Novartis, Pfizer, and Sanofi Pasteur. 18 
A.v.G. received research funding from Pfizer. M.A.P.S. has received grants to support 19 
research projects from GlaxoSmithKline, Novartis, Pfizer, and Sanofi Pasteur. This work is 20 
produced by the authors under the terms of the research training fellowships issued by the 21 
NIHR. The views expressed in this publication are those of the authors and not necessarily 22 
those of the National Health Service, NIHR, the Department of Health, or Public Health 23 
England. 24 
  25 
34 
 
References 1 
Papers of special note have been highlighted as either of interest (•) or of considerable 2 
interest (••) to readers.  3 
1.  Flexner S, Jobling JW. An analysis of four hundred cases of epidemic meningitis 4 
treated with the anti-meningitis serum. J Exp Med 10(5), 690-733 (1908). 5 
2.  Centers for Disease Control and Prevention. Meningococcal disease. In: Hamborsky J, 6 
Kroger A, Wolfe C, editors. Epidemiology and Prevention of Vaccine-Preventable 7 
Diseases. 13th ed. Washington, DC: Public Health Foundation; 2016. 8 
3.  Manchanda V, Gupta S, Bhalla P. Meningococcal disease: history, epidemiology, 9 
pathogenesis, clinical manifestations, diagnosis, antimicrobial susceptibility and 10 
prevention. Indian J Med Microbiol 24(1), 7-19 (2006). 11 
4.  Abio A, Neal KR, Beck CR. An epidemiological review of changes in meningococcal 12 
biology during the last 100 years. Pathog Glob Health 107(7), 373-380 (2013). 13 
5.  Al-Tawfiq JA, Clark TA, Memish ZA. Meningococcal disease: the organism, clinical 14 
presentation, and worldwide epidemiology. J Travel Med 17 Suppl, 3-8 (2010). 15 
6.  Cartwright K, Noah N, Peltola H. Meningococcal disease in Europe: epidemiology, 16 
mortality, and prevention with conjugate vaccines. Report of a European advisory 17 
board meeting Vienna, Austria, 6-8 October, 2000. Vaccine 19(31), 4347-4356 (2001). 18 
7.  Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. 19 
Pediatr Infect Dis J 23(12 Suppl), S274-S279 (2004). 20 
8.  Safadi MA, Barros AP. Meningococcal conjugate vaccines: efficacy and new 21 
combinations. J Pediatr (Rio J) 82(3 Suppl), S35-S44 (2006). 22 
9.  Stefanelli P, Rezza G. Impact of vaccination on meningococcal epidemiology. Hum 23 
Vaccin Immunother  (2015). 24 
10.  Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. 25 
Vaccine 30 Suppl 2, B3-B9 (2012). 26 
11.  Harrison LH, Pelton SI, Wilder-Smith A et al. The Global Meningococcal Initiative: 27 
recommendations for reducing the global burden of meningococcal disease. Vaccine 28 
29(18), 3363-3371 (2011). 29 
12.  National Advisory Committee on Immunization (NACI). An update on the invasive 30 
meningococcal disease and meningococcal vaccine conjugate recommendations. An 31 
Advisory Committee Statement (ACS). Can Commun Dis Rep 35(ACS-3), 1-40 (2009). 32 
13.  Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease. 33 
Recommendations of the Advisory Committee on Immunization Practices (ACIP). 34 
MMWR Recomm Rep 54(RR-7), 1-21 (2005). 35 
14.  Cohn AC, MacNeil JR, Harrison LH et al. Changes in Neisseria meningitidis disease 36 
epidemiology in the United States, 1998-2007: implications for prevention of 37 
meningococcal disease. Clin Infect Dis 50(2), 184-191 (2010). 38 
35 
 
15.  Cordeiro SM, Neves AB, Ribeiro CT et al. Hospital-based surveillance of 1 
meningococcal meningitis in Salvador, Brazil. Trans R Soc Trop Med Hyg 101(11), 2 
1147-1153 (2007). 3 
16.  Kimmel SR. Prevention of meningococcal disease. Am Fam Physician 72(10), 2049-4 
2056 (2005). 5 
17.  Yazdankhah SP, Caugant DA. Neisseria meningitidis: an overview of the carriage 6 
state. J Med Microbiol 53(Pt 9), 821-832 (2004). 7 
18.  Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by 8 
age: a systematic review and meta-analysis. Lancet Infect Dis 10(12), 853-861 (2010). 9 
19.  Trotter CL, Greenwood BM. Meningococcal carriage in the African meningitis belt. 10 
Lancet Infect Dis 7(12), 797-803 (2007). 11 
20.  Caugant DA, Maiden MC. Meningococcal carriage and disease--population biology 12 
and evolution. Vaccine 27 Suppl 2, B64-B70 (2009). 13 
21.  Read RC. Neisseria meningitidis; clones, carriage, and disease. Clin Microbiol Infect 14 
20(5), 391-395 (2014). 15 
22.  Halperin SA, Bettinger JA, Greenwood B et al. The changing and dynamic 16 
epidemiology of meningococcal disease. Vaccine 30 Suppl 2, B26-B36 (2012). 17 
23.  Pizza M, Rappuoli R. Neisseria meningitidis: pathogenesis and immunity. Curr Opin 18 
Microbiol 23, 68-72 (2015). 19 
24.  Murray RL, Britton J, Leonardi-Bee J. Second hand smoke exposure and the risk of 20 
invasive meningococcal disease in children: systematic review and meta-analysis. 21 
BMC. Public. Health. 12, 1062 (2012). 22 
25.  Chang Q, Tzeng YL, Stephens DS. Meningococcal disease: changes in epidemiology 23 
and prevention. Clin Epidemiol 4, 237-245 (2012). 24 
26.  Centers for Disease Control and prevention website [Internet]. Advisory Committee on 25 
Immunization Practices. Vaccine acronyms: vaccines included in the immunization 26 
schedules for children, adolescents, and adults. [Last updated 2015 May]. Available 27 
from: http://www.cdc.gov/vaccines/acip/committee/guidance/vac-abbrev.pdf.  28 
27.  Holst J, Oster P, Arnold R et al. Vaccines against meningococcal serogroup B disease 29 
containing outer membrane vesicles (OMV): lessons from past programs and 30 
implications for the future. Hum Vaccin Immunother 9(6), 1241-1253 (2013). 31 
28.  Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR. Use of Serogroup B 32 
Meningococcal Vaccines in Persons Aged >/=10 Years at Increased Risk for 33 
Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee 34 
on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep 64(22), 608-612 35 
(2015). 36 
29.  MacNeil JR, Rubin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin SW. Use of 37 
serogroup B meningococcal vaccines in adolescents and young adults: 38 
recommendations of the Advisory Committee on Immunization Practices, 2015. 39 
MMWR Morb Mortal Wkly Rep 64(41), 1171-1176 (2015). 40 
36 
 
30.  John TJ, Gupta S, Chitkara AJ, Dutta AK, Borrow R. An overview of meningococcal 1 
disease in India: knowledge gaps and potential solutions. Vaccine 31(25), 2731-2737 2 
(2013). 3 
31.  Safadi MA, de los Monteros LE, Lopez EL et al. The current situation of meningococcal 4 
disease in Latin America and recommendations for a new case definition from the 5 
Global Meningococcal Initiative. Expert Rev Vaccines 12(8), 903-915 (2013). 6 
32.  Safadi MA, Bettinger JA, Maturana GM, Enwere G, Borrow R. Evolving meningococcal 7 
immunization strategies. Expert Rev Vaccines 14(4), 505-517 (2015). 8 
33.  Safadi MA, O'Ryan M, Valenzuela Bravo MT et al. The current situation of 9 
meningococcal disease in Latin America and updated Global Meningococcal Initiative 10 
(GMI) recommendations. Vaccine 33(48), 6529-6536 (2015). 11 
34.  Vazquez JA, Taha MK, Findlow J, Gupta S, Borrow R. Global Meningococcal Initiative: 12 
guidelines for diagnosis and confirmation of invasive meningococcal disease. 13 
Epidemiol Infect 144(14), 3052-3057 (2016). 14 
35.  Lucidarme J, Hill DM, Bratcher HB et al. Genomic resolution of an aggressive, 15 
widespread, diverse and expanding meningococcal serogroup B, C and W lineage. J 16 
Infect 71(5), 544-552 (2015). 17 
36.  Safadi MA, Berezin EN, Arlant LH. Meningococcal disease: epidemiology and early 18 
effects of immunization programs. J Pediatric Infect Dis Soc 3(2), 91-93 (2014). 19 
37.  de Moraes JC, Kemp B, de Lemos APS et al. Prevalence, risk factors and molecular 20 
characteristics of meningococcal carriage among Brazilian adolescents. Pediatr Infect 21 
Dis J 34(11), 1197-1202 (2015). 22 
38.  Safadi MA, Carvalhanas TR, Paula de LA et al. Carriage rate and effects of vaccination 23 
after outbreaks of serogroup C meningococcal disease, Brazil, 2010. Emerg Infect Dis 24 
20(5), 806-811 (2014). 25 
39.  World Population Statistics website [Internet]. World Population Statistics. Population 26 
of Asia 2016. [Last updated 2016 Jan]. Available from: 27 
http://www.worldpopulationstatistics.com/population-of-asia/.  28 
40.  World Population Statistics website [Internet]. World Health Organization. WHO 29 
regional offices. [Last updated 2016]. Available from: 30 
http://www.who.int/about/regions/en/.  31 
41.  Jafri RZ, Ali A, Messonnier NE et al. Global epidemiology of invasive meningococcal 32 
disease. Popul. Health. Metr. 11(1), 17 (2013). 33 
42.  Cowling BJ, Caini S, Chotpitayasunondh T et al. Meningococcal disease in the Asia-34 
Pacific region: Findings and recommendations from the Global Meningococcal 35 
Initiative. Vaccine In press (accepted October 11, 2016) (2016). 36 
43.  World Health Organization website [Internet]. World Health Organization. WHO 37 
vaccine-preventable diseases: monitoring system. 2016 global summary. [Last 38 
updated 2016 Jul]. Available from: 39 
http://apps.who.int/immunization_monitoring/globalsummary.  40 
37 
 
44.  World Health Organization Western Pacific Region website [Internet]. World Health 1 
Organization Western Pacific Region. China, 2014. [Last updated 2015]. Available 2 
from: 3 
http://www.wpro.who.int/immunization/documents/epi_country_poster_2014_chn.pdf.  4 
45.  Australian Government Department of Health website [Internet]. Australian 5 
Government Department of Health. National immunisation program schedule. [Last 6 
updated 2016 Sep]. Available from: 7 
http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/nips.  8 
46.  Tanaka H, Kuroki T, Watanabe Y et al. [Isolation of Neisseria meningitidis from healthy 9 
persons in Japan]. Kansenshogaku. Zasshi 79(8), 527-533 (2005). 10 
47.  Takahashi H, Haga M, Sunagawa T et al. Meningococcal carriage rates in healthy 11 
individuals in Japan determined using Loop-Mediated Isothermal Amplification and oral 12 
throat wash specimens. J Infect Chemother 22(7), 501-504 (2016). 13 
48.  Hamada A, Fukushima S. Present situation and challenges of vaccinations for 14 
overseas travelers from Japan. J Infect Chemother 21(6), 405-409 (2015). 15 
49.  European Centre for Disease Prevention and Control. Surveillance of invasive bacterial 16 
diseases in Europe, 2012. Stockholm: ECDC; 2015. 17 
50.  Borrow R, Abad R, Trotter C, van der Klis FR, Vazquez JA. Effectiveness of 18 
meningococcal serogroup C vaccine programmes. Vaccine 31(41), 4477-4486 (2013). 19 
51.  Koroleva I. Meningococcal infection and purulent bacterial meningitis in Russia: 20 
analytical review. Moscow: Central Research Institute of Epidemiology, Russian 21 
Inspectorate for the Protection of Consumer Rights and Human Welfare; 2014. 22 
52.  Matosova S.V., Mironov K.O., Platonov A.E. et al. Molecular biological monitoring of 23 
Neisseria meningitidis in Moscow in the period 2011 to 2015. Epidemiologia i 24 
Infekcionnye bolezni (2), 4-9 (2016). 25 
53.  Meiring S, Cohen C, de Gouveia L et al. A decade of invasive meningococcal disease 26 
surveillance in South Africa: 2003-2012. The 16th International Congress on Infectious 27 
Diseases (ICID); April 2-5, 2014, Cape Town, South Africa. 28 
54.  von Gottberg A, du Plessis M, Cohen C et al. Emergence of endemic serogroup W135 29 
meningococcal disease associated with a high mortality rate in South Africa. Clin Infect 30 
Dis 46(3), 377-386 (2008). 31 
55.  Cohen C, Singh E, Wu HM et al. Increased incidence of meningococcal disease in 32 
HIV-infected individuals associated with higher case-fatality ratios in South Africa. 33 
AIDS 24(9), 1351-1360 (2010). 34 
56.  Simmons RD, Kirwan P, Beebeejaun K et al. Risk of invasive meningococcal disease 35 
in children and adults with HIV in England: a population-based cohort study. BMC Med 36 
13, 297 (2015). 37 
57.  Ibarz-Pavon AB, Morais L, Sigauque B et al. Epidemiology, molecular characterization 38 
and antibiotic resistance of Neisseria meningitidis from patients </=15 years in 39 
Manhica, rural Mozambique. PLoS One 6(6), e19717 (2011). 40 
38 
 
58.  Murray J, Agocs M, Serhan F et al. Global invasive bacterial vaccine-preventable 1 
diseases surveillance--2008-2014. MMWR Morb Mortal Wkly Rep 63(49), 1159-1162 2 
(2014). 3 
59.  Baccarini C, Ternouth A, Wieffer H, Vyse A. The changing epidemiology of 4 
meningococcal disease in North America 1945-2010. Hum Vaccin Immunother 9(1), 5 
162-171 (2013). 6 
60.  Government of Canada website [Internet]. Public Health Agency of Canada. Canadian 7 
immunization guide. [Last updated 2016 Feb]. Available from: http://www.phac-8 
aspc.gc.ca/publicat/cig-gci/p04-meni-eng.php.  9 
61.  Maiden MC, Ibarz-Pavon AB, Urwin R et al. Impact of meningococcal serogroup C 10 
conjugate vaccines on carriage and herd immunity. J Infect Dis 197(5), 737-743 11 
(2008). 12 
62.  Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from 13 
meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 14 
326(7385), 365-366 (2003). 15 
63.  GOV UK website [Internet]. Public Health England. Meningococcal meningitis and 16 
septicaemia notifiable. [Last updated 2015 Sep]. Available from: 17 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/462629/18 
2904512_Green_Book_Chapter_22_v6_0W.PDF.  19 
64.  Kristiansen PA, Diomande F, Ba AK et al. Impact of the serogroup A meningococcal 20 
conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis 56(3), 21 
354-363 (2013). 22 
65.  Daugla DM, Gami JP, Gamougam K et al. Effect of a serogroup A meningococcal 23 
conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in 24 
Chad: a community study [corrected]. Lancet 383(9911), 40-47 (2014). 25 
66.  Jeppesen CA, Snape MD, Robinson H et al. Meningococcal carriage in adolescents in 26 
the United Kingdom to inform timing of an adolescent vaccination strategy. J Infect 27 
71(1), 43-52 (2015). 28 
67.  Caugant DA, Kristiansen PA, Wang X et al. Molecular characterization of invasive 29 
meningococcal isolates from countries in the African meningitis belt before introduction 30 
of a serogroup A conjugate vaccine. PLoS One 7(9), e46019 (2012). 31 
68.  Kretz CB, Retchless AC, Sidikou F et al. Whole-Genome Characterization of Epidemic 32 
Neisseria meningitidis Serogroup C and Resurgence of Serogroup W, Niger, 2015. 33 
Emerg. Infect Dis. 22(10), 1762-1768 (2016). 34 
69.  Meningitis Vaccine Project website [Internet]. PATH. A public health breakthrough. 35 
[Last updated 2015]. Available from: http://www.meningvax.org/.  36 
70.  World Health Organization website [Internet]. World Health Organization. WHO 37 
meningococcal meningitis. Fact sheet 141. [Last updated 2015 Nov]. Available from: 38 
http://www.who.int/mediacentre/factsheets/fs141/en/.  39 
71.  Lingani C, Bergeron-Caron C, Stuart JM et al. Meningococcal Meningitis Surveillance 40 
in the African Meningitis Belt, 2004-2013. Clin Infect Dis 61 Suppl 5, S410-S415 41 
(2015). 42 
39 
 
72.  Karachaliou A, Conlan AJ, Preziosi MP, Trotter CL. Modeling long-term vaccination 1 
strategies with MenAfriVac in the African meningitis belt. Clin Infect Dis 61 Suppl 5, 2 
S594-S600 (2015). 3 
73.  Global Advisory Committee on Vaccine Safety, 3-4 December 2009. Wkly Epidemiol 4 
Rec 85(5), 29-33 (2010). 5 
74.  World Health Organization website [Internet]. World Health Organization. Affordable 6 
and effective vaccine brings Africa close to elimination of meningitis A. [Last updated 7 
2015 Nov]. Available from: http://www.who.int/features/2015/meningitis-africa-8 
elimination/en/.  9 
75.  Meningitis Vaccine Project website [Internet]. PATH. WHO surveillance bulletins. [Last 10 
updated 2016]. Available from: http://www.meningvax.org/epidemic-updates.php.  11 
76.  Meningococcal disease control in countries of the African meningitis belt, 2014. Wkly 12 
Epidemiol Rec 90(13), 123-131 (2015). 13 
77.  World Health Organization website [Internet]. World Health Organization Strategic 14 
Advisory Group of Experts (SAGE) on Immunization. SAGE October 2014. [Last 15 
updated 2014 Oct]. Available from: 16 
http://www.who.int/immunization/sage/meetings/2014/october/Yellow-17 
bookSAGE2014_final.pdf.  18 
78.  World Health Organization website [Internet]. World Health Organization. Serogroup C 19 
in the meningitis belt: facing the challenge. Report of meeting held in Geneva, October 20 
2015 . [Last updated 2015 Nov]. Available from: 21 
http://www.who.int/csr/disease/meningococcal/Facing_NmC_Epidemics_Meningitis_B22 
elt.pdf.  23 
79.  Preparedness for outbreaks of meningococcal meningitis due to Neisseria meningitidis 24 
serogroup C in Africa: recommendations from a WHO expert consultation. Wkly 25 
Epidemiol Rec. 90(47), 633-636 (2015). 26 
80.  Funk A, Uadiale K, Kamau C, Caugant DA, Ango U, Greig J. Sequential outbreaks due 27 
to a new strain of Neisseria meningitidis serogroup C in northern Nigeria, 2013-14. 28 
PLoS Curr 6 (2014). 29 
81.  Taha MK, Achtman M, Alonso JM et al. Serogroup W135 meningococcal disease in 30 
Hajj pilgrims. Lancet 356(9248), 2159 (2000). 31 
82.  Taha MK, Parent Du Chatelet I, Schlumberger M et al. Neisseria meningitidis 32 
serogroups W135 and A were equally prevalent among meningitis cases occurring at 33 
the end of the 2001 epidemics in Burkina Faso and Niger. J Clin Microbiol 40(3), 1083-34 
1084 (2002). 35 
83.  Mayer LW, Reeves MW, Al-Hamdan N et al. Outbreak of W135 meningococcal 36 
disease in 2000: not emergence of a new W135 strain but clonal expansion within the 37 
electophoretic type-37 complex. J Infect. Dis 185(11), 1596-1605 (2002). 38 
84.  Ferreira E, Dias R, Giorgini D, Canica M, Taha MK. Neisseria meningitidis serogroup 39 
W135 in Portugal: presence of the ST-11/ET-37 clonal complex. Pathol Biol (Paris) 40 
56(2), 94-96 (2008). 41 
40 
 
85.  Lemos AP, Harrison LH, Lenser M, Sacchi CT. Phenotypic and molecular 1 
characterization of invasive serogroup W135 Neisseria meningitidis strains from 1990 2 
to 2005 in Brazil. J Infect 60(3), 209-217 (2010). 3 
86.  National Institute of Infectious Diseases website [Internet]. Kanai M, Hachisu Y, 4 
Fukusumi M et al. Meningococcal disease cases in Scotland and Sweden, following 5 
attendance at the World Scout Jamboree, Yamaguchi, Japan, July 28-August 8, 2015. 6 
[Last updated 2015 Aug]. Available from: http://www.nih.go.jp/niid/en/id/997-disease-7 
based/sa/bac-%20%20%20%20megingitis/idsc/iasr-in/5879-pr4272e.html.  8 
87.  Weidlich L, Baethgen LF, Mayer LW et al. High prevalence of Neisseria meningitidis 9 
hypervirulent lineages and emergence of W135:P1.5,2:ST-11 clone in Southern Brazil. 10 
J Infect 57(4), 324-331 (2008). 11 
88.  Valenzuela MT, Moreno G, Vaquero A et al. [Emergence of W135 meningococcal 12 
serogroup in Chile during 2012]. Rev Med Chil 141(8), 959-967 (2013). 13 
89.  Abad R, Lopez EL, Debbag R, Vazquez JA. Serogroup W meningococcal disease: 14 
global spread and current affect on the Southern Cone in Latin America. Epidemiol 15 
Infect 142(12), 2461-2470 (2014). 16 
90.  Mustapha MM, Marsh JW, Krauland MG et al. Genomic epidemiology of hypervirulent 17 
serogroup W, ST-11 Neisseria meningitidis. EBioMedicine 2(10), 1447-1455 (2015). 18 
91.  LinkedIn SlideShare website [Internet]. Safadi MA. Emergence of a new virulent 19 
meningicoccal W sequence type 11 in South America: experience, control measures 20 
and impact. [Last updated 2015 Nov]. Available from: 21 
http://www.slideshare.net/meningitis/dr-marco-safadi-mrfs-meningitis-septicaemia-in-22 
children-adults-2015.  23 
92.  Ladhani SN, Beebeejaun K, Lucidarme J et al. Increase in endemic Neisseria 24 
meningitidis capsular group W sequence type 11 complex associated with severe 25 
invasive disease in England and Wales. Clin Infect Dis 60(4), 578-585 (2015). 26 
93.  Vesikari T, Esposito S, Prymula R et al. Immunogenicity and safety of an 27 
investigational multicomponent, recombinant, meningococcal serogroup B vaccine 28 
(4CMenB) administered concomitantly with routine infant and child vaccinations: 29 
results of two randomised trials. Lancet 381(9869), 825-835 (2013). 30 
94.  FDA website [Internet]. U.S.Food and Drug Administration. FDA News Release: FDA 31 
approves a second vaccine to prevent serogroup B meningococcal disease. [Last 32 
updated 2015 Jan]. Available from: 33 
http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm431370.htm.  34 
95.  European Medicine Agency website [Internet]. European Medicines Agency. Summary 35 
of the European public assessment report (EPAR) for Bexsero. [Last updated 2015 36 
Mar]. Available from: 37 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/00238 
333/human_med_001614.jsp&mid=WC0b01ac058001d124.  39 
96.  Shirley M, Dhillon S. Bivalent rLP2086 vaccine (Trumenba®): a review in active 40 
immunization against invasive meningococcal group B disease in individuals aged 10-41 
25 years. BioDrugs 29(5), 353-361 (2015). 42 
41 
 
97.  FDA website [Internet]. U.S.Food and Drug Administration. FDA News Release: First 1 
vaccine approved by FDA to prevent serogroup B Meningococcal disease. [Last 2 
updated 2014 Oct]. Available from: 3 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm420998.htm.  4 
98.  Donnelly J, Medini D, Boccadifuoco G et al. Qualitative and quantitative assessment of 5 
meningococcal antigens to evaluate the potential strain coverage of protein-based 6 
vaccines. Proc Natl Acad Sci U S A 107(45), 19490-19495 (2010). 7 
99.  Hong E, Giuliani MM, Deghmane AE et al. Could the multicomponent meningococcal 8 
serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X 9 
outbreaks in Africa? Vaccine 31(7), 1113-1116 (2013). 10 
100.  McNamara LA, Shumate AM, Johnsen P et al. First use of a serogroup B 11 
meningococcal vaccine in the US in response to a university outbreak. Pediatrics 12 
135(5), 798-804 (2015). 13 
101.  Medini D, Stella M, Wassil J. MATS: global coverage estimates for 4CMenB, a novel 14 
multicomponent meningococcal B vaccine. Vaccine 33(23), 2629-2636 (2015). 15 
102.  Patel M. Use of a novel serogroup B meningococcal vaccine in response to two 16 
university outbreaks in the US. XIXth Pathogenic Neisseria Conference; October 12-17 
17, 2014, Asheville, NC, USA. 18 
103.  GOV UK website [Internet]. Public Health England. National enhanced surveillance of 19 
vaccination programmes targeting invasive meningococcal disease in England. [Last 20 
updated 2015 Sep]. Available from: 21 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/457723/22 
MeningoEnhancedSurveillancePlan_01092015_v1.1.pdf.  23 
104.  INSPQ website [Internet]. Institut National de Santé Publique Québec. Rapport 24 
intérimaire de surveillance de la sécurité de la première dose du vaccin contre le 25 
méningocoque de sérogroupe B au Saguenay-Lac-Saint-Jean. [Last updated 2014 26 
Sep]. Available from: https://www.inspq.qc.ca/publications/1885.  27 
105.  INSPQ website [Internet]. Institut National de Santé Publique Québec. Avis sur la 28 
pertinence d'une intervention visant à contrôler une incidence élevée d'infections 29 
invasives à méningocoque de sérogroupe B dans l'Est du Québec. [Last updated 2014 30 
Apr]. Available from: https://www.inspq.qc.ca/publications/1801.  31 
106.  Law DK, Lefebvre B, Gilca R et al. Characterization of invasive Neisseria meningitidis 32 
strains from Quebec, Canada, during a period of increased serogroup B disease, 33 
2009-2013: phenotyping and genotyping with special emphasis on the non-34 
carbohydrate protein vaccine targets. BMC Microbiol 15, 143 (2015). 35 
107.  Pan_Canadian Public Health Network website [Internet]. Meningococcal B Pilot Project 36 
Task Group . The recommended use of the multicomponent meningococcal B 37 
(4CMenB) vaccine in Canada. [Last updated 2014 Mar]. Available from: 38 
http://publications.gc.ca/collections/collection_2014/aspc-phac/HP40-103-2014-39 
eng.pdf.  40 
108.  Government of Canada website [Internet]. Public Health Agency of Canada. Advice for 41 
the use of the multicomponent meningococcal serogroup B (4CMenB) vaccine. [Last 42 
updated 2014 Apr]. Available from: 43 
http://publications.gc.ca/site/eng/463960/publication.html.  44 
42 
 
109.  De Wals P. Results of a mass immunization campaign with a 4-components serogroup 1 
B meningococcal vaccine in Quebec, Canada. World Society for Pediatric Infectious 2 
Diseases; November 18-21, 2015, Rio de Janeiro, Brazil. 3 
110.  Delbos V, Lemee L, Benichou J et al. Impact of MenBvac, an outer membrane vesicle 4 
(OMV) vaccine, on the meningococcal carriage. Vaccine. 31(40), 4416-4420 (2013). 5 
111.  Meningitis Research Foundation website [Internet]. Meningitis Research Foundation. 6 
MenB. [Last updated 2015]. Available from: http://www.meningitis.org/menb.  7 
112.  Confederation of Meningitis Organisations website [Internet]. Confederation of 8 
Meningitis Organisations. About us. [Last updated 2016]. Available from: 9 
http://www.comomeningitis.org/about-us/.  10 
113.  Confereration of Meningitis Organisations website [Internet]. Confederation of 11 
Meningitis Organisations. World Meningitis Day 2015. [Last updated 2015 May]. 12 
Available from: http://www.comomeningitis.org/news-and-events/world-meningitis-13 
day/wmd-2015/.  14 
114.  Confederation of Meningitis Organisations website [Internet]. Booy R, Robinson P, 15 
Gold R, Stuart J, Weil-Olivier C. The meningitis B debate. [Last updated 2015 Sep]. 16 
Available from: http://www.comomeningitis.org/blog/2015/09/the-meningococcal-b-17 
vaccine-debate/.  18 
115.  Confederation of Meningitis Organisations website [Internet]. Confederation of 19 
Meningitis Organisations. Life course meningitis initiative. [Last updated 2016 Jan]. 20 
Available from: http://www.comomeningitis.org/projects/life-course-immunisation-21 
initiative/.  22 
116.  Trotter CL, Edmunds WJ. Reassessing the cost-effectiveness of meningococcal 23 
serogroup C conjugate (MCC) vaccines using a transmission dynamic model. Med 24 
Decis Making 26(1), 38-47 (2006). 25 
117.  Read RC, Baxter D, Chadwick DR et al. Effect of a quadrivalent meningococcal ACWY 26 
glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: 27 
an observer-blind, phase 3 randomised clinical trial. Lancet 384(9960), 2123-2131 28 
(2014). 29 
118.  Trotter CL, Gay NJ, Edmunds WJ. Dynamic models of meningococcal carriage, 30 
disease, and the impact of serogroup C conjugate vaccination. Am J Epidemiol 162(1), 31 
89-100 (2005). 32 
119.  Christensen H, Hickman M, Edmunds WJ, Trotter CL. Introducing vaccination against 33 
serogroup B meningococcal disease: an economic and mathematical modelling study 34 
of potential impact. Vaccine 31(23), 2638-2646 (2013). 35 
120.  Mustapha MM, Marsh JW, Harrison LH. Global epidemiology of capsular group W 36 
meningococcal disease (1970-2015): Multifocal emergence and persistence of 37 
hypervirulent sequence type (ST)-11 clonal complex. Vaccine. 34(13), 1515-1523 38 
(2016). 39 
121.  Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned 40 
from serogroup C conjugate vaccination programs. Expert. Rev. Vaccines. 8(7), 851-41 
861 (2009). 42 
43 
 
122.  Taha MK, Claus H, Lappann M et al. Evolutionary events associated with an outbreak 1 
of meningococcal disease in men who have sex with men. PLoS One 11(5), e0154047 2 
(2016). 3 
 4 
 5 
  6 
44 
 
Tables 1 
Table 1. Meningococcal disease vaccine coverage and manufacturers 2 
Vaccine Coverage 
(N. meningitides strain) 
Manufacturer 
Polysaccharide vaccines 
Various One or more of A, C, W, 
and/or Y 
Various (available for >40 
years) 
Protein conjugate vaccines 
Meningitec® C Nuron Biotech Inc, Exton, 
PA, USA 
Menjugate® C GlaxoSmithKline Biologicals 
SA, Rixensart, Belgium 
NeisVac-C® C Pfizer Inc, New York, USA 
MenAfriVac® A Serum Institute of India Ltd, 
Pune, India 
Menactra® A, C, W, Y Sanofi Pasteur SA, Lyon, 
France 
Menveo® A, C, W, Y GlaxoSmithKline Biologicals 
SA, Rixensart, Belgium 
Nimenrix® A, C, W, Y Pfizer Inc, New York, USA 
Combination conjugate vaccines 
Menitorix® C + Haemophilus 
influenzae type b 
GlaxoSmithKline Biologicals 
SA, Rixensart, Belgium 
MenHibrix® C, Y + Haemophilus 
influenzae type b 
GlaxoSmithKline Biologicals 
SA, Rixensart, Belgium 
Subcapsular meningococcal antigen vaccines 
Trumenba® B Wyeth Pharmaceuticals Inc. 
(a subsidiary of Pfizer Inc.), 
Philadelphia, PA, USA, 
Bexsero® B GlaxoSmithKline Biologicals 
SA, Rixensart, Belgium 
 3 
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Table 2. The GMI Global Recommendations for MD [33]. 1 
1 Country-specific approaches to prevention of MD by vaccination are needed because 
of disease variation. 
2 Country-specific meningococcal policy should be based on local epidemiology and 
economic considerations. 
3 Continued funding of the introduction of MenAfriVac® is an important global and 
regional public health priority. 
4 The Meningitis Vaccine Project model should be considered when developing other 
products with markets that are primarily or exclusively in developing countries. 
5 Travelers to high-risk areas should be vaccinated against invasive MD. 
6 Vaccines against all clinically relevant serogroups (MenA, B, C, W, X, and Y) should be 
developed. 
7 Conjugate vaccines should replace PSVs whenever cost, availability, licensing, and 
immunization policy allow. However, PSVs are still recommended where conjugate 
vaccines are not available. 
8 Laboratory-based surveillance for MD should be strengthened (or initiated) to 
determine the true burden of disease. 
GMI: Global Meningococcal Initiative; MD: Meningococcal disease; PSV: Polysaccharide 2 
vaccine. 3 
Adapted from Vaccine, Vol 33, Marco Aurélio P. Sáfadi, Miguel O’Ryan, Maria Teresa 4 
Valenzuela Bravo, Maria Cristina C. Brandileone, Maria Cecília O. Gorla, Ana Paula S. de 5 
Lemos, Gabriela Moreno, Julio A. Vazquez, Eduardo L. López, Muhamed-Kheir Taha, Ray 6 
Borrow, on behalf of the Global Meningococcal Initiative. The current situation of 7 
meningococcal disease in Latin America and updated Global Meningococcal Initiative (GMI) 8 
recommendations, Pages No. 6529–6536, Copyright (2015), with permission from Elsevier. 9 
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Table 3. The GMI Updated Global Recommendations regarding strategies for the 1 
prevention of MD and the importance of herd protection. 2 
1 The GMI advocates WGS and/or collaborations enabling WGS, as well as the 
sharing of sequence data in the public domain. 
2 The GMI recommends vaccination of those attending large and prolonged events 
such events such as the World Scout Jamboree, given the increased risk of contact 
with the pathogen. 
3 The GMI recognizes the importance of ongoing vigilance in the face of this dynamic 
disease and calls for continued support and expansion of vaccination and 
surveillance programs. 
4 Building herd protection and stopping acquisition are important, as they prevent 
transmission of MD; therefore, the GMI recommends vaccination of those age 
groups with the highest carriage rates (particularly adolescents). 
5 The use of subcapsular vaccines (e.g., MenB vaccines) should be based on 
molecular typing and/or local data of strain coverage. 
6 The GMI recognizes the importance and impact of MD advocacy and awareness 
campaigns and strongly supports such activities. 
7 The GMI underlines the need for promoting modeling studies to help the decision-
making process. 
GMI: Global Meningococcal Initiative; MD: Meningococcal disease; WGS: Whole-genome 3 
sequencing.  4 
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Figures 1 
Figure 1. Incidence rates before and after routine MenC vaccination in Brazil, 2008–2 
2014. Adapted with permission from Safadi MA, Berezin EN, Arlant LH. 3 
Meningococcal Disease: Epidemiology and Early Effects of Immunization Programs. 4 
J Pediatric. Infect Dis Soc. 3(2), 91-93 (2014). Supplemented with unpublished data 5 
for 2013–2014.. 6 
 7 
 8 
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Figure 2. Impact of MenC conjugate vaccines in reducing carriage, leading to herd 1 
protection in the UK. (A) Reduction in MenC carriage [61] (immunized individuals 2 
aged 15–19 years). (B) Direct and herd protection [62] against MenC (attack rates in 3 
infants and overall attack rate reduction in age group 2 months to 18 years)  4 
  5 
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Figure 3. Effect of MenAfriVac® vaccination on number of meningitis cases (data for 1 
African countries under enhanced MD surveillance) [75].  2 
Reproduced with permission from WHO surveillance bulletins. http://www meningvax 3 
org/epidemic-updates php (2016) http://www.meningvax.org/epidemic-updates.php., 4 
last accessed October 4, 2016. 5 
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Figure 4. Incidence of MD in Chile in children between 9 months and <5 years of 1 
age before and after introduction of quadrivalent Neisseria meningitidis (MenACWY) 2 
vaccination in 2012 (unpublished data from Instituto de Salud Pública de Chile, 3 
Laboratorio de Agentes de Meningitis Bacteriana, Santiago, Chile). 4 
MD: meningococcal disease; Men: Neisseria meningitidis serogroup. 5 
 6 
 7 
 8 
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Figure 5. Average annual number of invasive MD cases reported in Canadian 1 
provinces, 2007–2011. © All rights reserved. The Recommended Use of the 2 
Multicomponent Meningococcal B (4CMenB) Vaccine in Canada: Common 3 
Guidance Statement. Public Health Agency of Canada, 2014. Reproduced with 4 
permission from the Minister of Health, 2016. 5 
http://publications.gc.ca/collections/collection_2014/aspc-phac/HP40-103-2014-6 
eng.pdf (2014), last accessed October 4, 2016. 7 
 8 
AB: Alberta; BC: British Columbia; MB: Manitoba; MD: meningococcal disease; NB: New 9 
Brunswick; NL: Newfoundland and Labrador; NS: Nova Scotia; NT: Northwest Territories; 10 
NU: Nunavut; ON: Ontario; PE: Prince Edward Island; QC: Quebec; SK: Saskatchewan; YK: 11 
Yukon. 12 
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